A monoclonal antibody created by the Nanobiotechnology for Diagnostics group (Nb4D) at the Institute of Advanced Chemistry of ...

Commentary: While vaccines stimulate the body to produce an immune response, monoclonal antibodies skip a few steps and ...

The oncology monoclonal antibodies market presents opportunities through technological advancements, new product launches, ...

Fc receptors function as the essential bridge between the innate and adaptive immune systems. When antibodies bind to their ...

PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

The demand from both new and current investors highlights confidence in CytoDyn’s clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for ...

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business ...

Elia addressed the DECLARATION study for VYD2311: "We were recently notified that the DECLARATION clinical trial has reached target enrollment...may modestly over enroll as sites are permission to ...

Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript March 5, 2026 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06428 EPS, expectations were $-0.06. Operator: Good day, ...

New research advances an Epstein–Barr virus vaccine, while another study detects higher levels of microplastics in prostate cancer tumors.